HCM vs ZLAB vs LEGN vs CAN vs ABBV

For growth investors, Canaan Inc.

(CAN) is the stronger pick with 96. 7% revenue growth year-over-year, versus -24. 8% for HUTCHMED (China) Limited (HCM). HUTCHMED (China) Limited (HCM) offers the better valuation at 60. 5x trailing P/E (41. 7x forward), making it the more compelling value choice. Analysts rate HUTCHMED (China) Limited (HCM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, HUTCHMED (China) Limited (HCM) is the cheapest at 60.

5x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -92. 3% for Canaan Inc. (CAN). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus CAN's -90. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Canaan Inc. 's 4. 41β — meaning CAN is approximately 1204% more volatile than ABBV relative to the S&P 500. On balance sheet safety, HUTCHMED (China) Limited (HCM) carries a lower debt/equity ratio of 12% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Canaan Inc.

(CAN) is pulling ahead at 96. 7% versus -24. 8% for HUTCHMED (China) Limited (HCM). On earnings-per-share growth, the picture is similar: Canaan Inc. grew EPS 51. 1% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -39. 7% for Canaan Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -49. 9% for ZLAB. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 3x forward P/E versus 118. 1x for Legend Biotech Corporation — 103. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAN: 336. 9% to $2. 25.

In this comparison, ABBV (3.

2% yield) pays a dividend. HCM, ZLAB, LEGN, CAN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Canaan Inc. (CAN) carries a higher beta of 4. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, CAN: -90. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HCM (Healthcare) and ZLAB (Healthcare) and LEGN (Healthcare) and CAN (Technology) and ABBV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HCM is a small-cap quality compounder stock; ZLAB is a small-cap high-growth stock; LEGN is a small-cap high-growth stock; CAN is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while HCM, ZLAB, LEGN, CAN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.